GLP-1 & compounded medication availability in Massachusetts (2026)

Massachusetts rebuilt its compounding oversight from the ground up after the 2012 New England Compounding Center tragedy, and today it runs the most rigorous pharmacy-licensure framework in the country: specialized compounding licenses, unannounced inspections, and since 2025 a dedicated license that every out-of-state pharmacy must hold before shipping a single prescription into the commonwealth. None of that keeps medications from reaching Boston or the Berkshires; it decides who may send them. Here is the ten-line picture for Massachusetts addresses.

Conditional state

Availability facts last reviewed: November 16, 2026

All ten lines at a glance for Massachusetts

Availability of all ten OrderlyMeds product lines in Massachusetts, with typical delivery times and notes
Product lineAvailable in Massachusetts?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Ships from licensed partner pharmacies holding the commonwealth’s nonresident credential.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same flat national price at every dose, Cape Cod to Pittsfield.
NAD+ Yes 8–10 business days Fulfilled through the longevity line’s partner pharmacies.
Sermorelin Yes 8–10 business days Orders follow the standard telehealth evaluation flow.
Glutathione No N/A A gap in the OrderlyMeds formulary today, shown as one.
BPC-157 Yes 8–10 business days Compounded injectable on a patient-specific prescription; federal record below.
TB-500 Yes 8–10 business days Compounded injectable; its own federal record is stated below.
KPV No N/A Not carried, because our peptide formulary is injectable-only and KPV is not an injectable line.
Epitalon Yes 8–10 business days Compounded injectable; read its federal section below.
MOTS-c Yes 8–10 business days Compounded injectable; its federal record differs from its siblings’. See below.

An honest No beats a padded catalog. Two of the ten rows above are gaps, and we show them as gaps. Massachusetts facts on this page were last reviewed on November 16, 2026.

Research peptides in Massachusetts: BPC-157, TB-500, KPV, Epitalon & MOTS-c

OrderlyMeds carries four of these five lines for Massachusetts addresses: BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable on a patient-specific prescription. KPV is the odd one out: our peptide formulary is injectable-only and KPV is not compounded that way. Massachusetts adds no peptide-specific layer of its own, so the facts that matter here are federal, and each line’s federal record is stated below in full, on every page in this family, whether or not the line ships to you.

BPC-157 in Massachusetts

In the OrderlyMeds formulary for Massachusetts as a compounded injectable, dispensed on a patient-specific prescription through a pharmacy credentialed for the commonwealth. Its federal record follows.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Massachusetts

Ships to Massachusetts addresses as a compounded injectable on a patient-specific prescription. The two federal facts below are the ones that matter before ordering.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Massachusetts

Not in our formulary for Massachusetts or anywhere else, because we compound peptides as injectables only and KPV is not one of them.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Massachusetts

Available to Massachusetts patients as a compounded injectable under a patient-specific prescription. Its federal record is stated next.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Massachusetts

Carried for Massachusetts as a compounded injectable on a patient-specific prescription. Its federal record is its own, not a copy of its siblings’, and is stated below.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Massachusetts’s pharmacy regulators say about compounded medications

Massachusetts earned its reputation the hard way: the 2012 meningitis outbreak traced to a Framingham compounder killed more than 60 people nationwide, and the legislature’s answer became the template other states still study. The commonwealth’s Board of Registration in Pharmacy now oversees one of the toughest two-layer frameworks in the country: strict rules on who may compound, and strict rules on who may ship into the state at all.

After the 2012 NECC outbreak, Massachusetts enacted Chapter 159 of the Acts of 2014, which created specialized licenses for sterile and complex non-sterile compounding pharmacies (resident and nonresident), required USP-standard compliance and compounded-drug labeling, and mandated unannounced inspections and adverse-event reporting. Source: Massachusetts Session Laws, Chapter 159 of the Acts of 2014.

Under M.G.L. c.112 §39J, no out-of-state pharmacy may dispense or ship prescription drugs into the commonwealth without a nonresident pharmacy license from the Board of Registration in Pharmacy, and sterile or complex non-sterile compounded preparations must come from a pharmacy holding the corresponding nonresident compounding license; the board implemented this licensing regime in 2025. Sources: M.G.L. c.112 §39J · Board of Registration in Pharmacy.

Massachusetts permits providers to evaluate patients and issue prescriptions on the basis of a telehealth encounter within the applicable standard of care; no prior in-person visit is required for the non-controlled medications on this page. Source: CCHP Policy Finder — Massachusetts.

No GLP-1-specific or peptide-specific restriction has been published by the Board of Registration in Pharmacy; the commonwealth’s oversight operates through the licensure and inspection framework above rather than medication-by-medication positions. Source: Board of Registration in Pharmacy.

What this means for a Massachusetts patient is mostly invisible: the same online evaluation, the same flat national pricing, the same tracked delivery. The difference is that the pharmacy filling the order has cleared a higher bar to be in the commonwealth at all. We consider that a feature. A state that inspects its suppliers without warning is a state where a mail-order prescription is worth trusting.

Massachusetts availability FAQs

Is compounded semaglutide available in Massachusetts?

Yes. OrderlyMeds ships compounded semaglutide to Massachusetts addresses through partner pharmacies holding the commonwealth’s nonresident pharmacy credential, at the same flat national price charged everywhere.

Does Massachusetts's strict compounding oversight affect my order?

Not in any way you’ll feel. The oversight falls on the pharmacy, through specialized licensure and unannounced inspections, rather than on the patient. Your flow is the standard online evaluation and a tracked shipment.

Which research peptides ship to Massachusetts?

BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable on a patient-specific prescription. KPV is the exception, because ours is an injectable-only formulary and KPV isn’t one. Each line’s cited federal record is in its section above.

How long does delivery to Massachusetts take?

The published window is 8–10 business days from signup, with tracking sent the moment it exists.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone